First report on overall survival (OS) and improved progression free survival (PFS) in a completed phase 2a study of melflufen in advanced relapsed refractory multiple myeloma (RRMM)

Authors
Category Primary study
JournalBlood
Year 2017
This article has no abstract
Epistemonikos ID: 9cb5ddb7ee190288a41946d17bef9db491b7cd0e
First added on: Feb 08, 2025